Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Cabanillas

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Cancer|December 6, 2002
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 17, 2003
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocationsAndre Goy, Latha Ramdas, Yvonne K Remache, et al.
Cancer|July 13, 2002
International prognostic index-based outcomes for diffuse large B-cell lymphomasRichard B Wilder, Maria A Rodriguez, L Jeffrey Medeiros, et al.
Puerto Rico Health Sciences Journal|June 27, 2014
Clinical and pathological features of colorectal cancer in patients at a community hospital in Puerto RicoMaribel Cotto, Kathia E Rosado-Orozco, Rafael Rizek, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
Blood|October 24, 2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou, Peter McLaughlin, Anas Younes, et al.
American Journal of Clinical Oncology|February 6, 2004
Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Larry B Levy, et al.
European Journal of Haematology|August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Cancer|December 6, 2002
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 17, 2003
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocationsAndre Goy, Latha Ramdas, Yvonne K Remache, et al.
Cancer|July 13, 2002
International prognostic index-based outcomes for diffuse large B-cell lymphomasRichard B Wilder, Maria A Rodriguez, L Jeffrey Medeiros, et al.
Puerto Rico Health Sciences Journal|June 27, 2014
Clinical and pathological features of colorectal cancer in patients at a community hospital in Puerto RicoMaribel Cotto, Kathia E Rosado-Orozco, Rafael Rizek, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2002
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapyGregory M Chronowski, Richard B Wilder, Susan L Tucker, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
Blood|October 24, 2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou, Peter McLaughlin, Anas Younes, et al.
American Journal of Clinical Oncology|February 6, 2004
Second malignancies after chemotherapy and radiotherapy for Hodgkin diseaseGregory M Chronowski, Richard B Wilder, Larry B Levy, et al.
European Journal of Haematology|August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Pageof 11